Key Drivers
- Liquidity cushion
- Margin collapse
- Dilution risk
AIAI Summary
VALN has shifted into a high-risk binary catalyst story: EMA validation of the Lyme vaccine with Pfizer creates meaningful upside optionality, but collapsing gross margins, ongoing cash burn/dilution, and a valuation already pricing in progress mean the rally should be viewed as event-driven until approval and commercialization are proven.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Margin collapse
- •Dilution risk
VALN has solid near-term liquidity but deeply negative margins, weak cash generation, rising leverage, and dilution, so it remains a high-risk turnaround despite adequate balance-sheet coverage.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Gap breakout
- •Stretched rally
VALN's breakout to $7.13 from $5.65 confirms a strong uptrend and price discovery, but the fast gap-up leaves it vulnerable to a near-term pullback unless it holds the $5.65-$5.30 support band.
Sharp gap higher from $5.65 to $7.13 signals elevated pullback risk
Sentiment & News
Key News Insights:
- •Lower H1 revenue
- •Wider losses
- •Lyme catalyst
Valneva reported weaker H1 2026 revenue and wider losses, but kept full-year guidance unchanged while highlighting cash, restructuring, and potential regulatory progress on its Pfizer-partnered Lyme vaccine.
The update is mildly negative on current performance but supportive for sentiment if guidance holds and Lyme vaccine progress advances
Similar Companies in Healthcare
Other companies in the same sector with AI ratings